This announcement is a separate document:
信立泰：关于获得碱基编辑药物YOLT-101独家许可权益的公告
Xinlitai: Announcement on obtaining exclusive licensing rights for the base-editing drug YOLT-101
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated